Last reviewed · How we verify

NCT05809089

HFNO in Pneumonia Patients Presenting With Acute Hypoxemic Respiratory Failure

Completed NA Last updated 25 August 2023
What this trial tests

NA trial testing High flow nasal cannula (HFNC) in Pneumonia in 200 participants. Completed in 20 February 2023.

Timeline
20 November 2020
Primary endpoint
20 January 2023
20 February 2023

Quick facts

Lead sponsorAssiut University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposesupportive care
Enrollment200
Start date20 November 2020
Primary completion20 January 2023
Estimated completion20 February 2023
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Assiut University

Who can join

Adults 18 to 70, any sex, with Pneumonia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

High-flow nasal oxygen (HFNO) therapy is an upcoming and beneficial modality for patients with acute hypoxemic respiratory failure (AHRF). To evaluate whether early use of HFNO in pneumonia patients with (AHRF) can reduce the need for invasive ventilation.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Outcome of Early Initiation of High-flow Nasal Oxygen Therapy among Pneumonia Patients Presenting with Acute Hypoxemic Respiratory Failure.
    Magdy DM. · · 2024 · cited 1× · PMID 39239186 · DOI 10.5005/jp-journals-10071-24769

Verify or expand the search:

Other trials of High flow nasal cannula (HFNC)

Trials testing the same drug.

Other recruiting trials for Pneumonia

Currently open trials in the same condition.

Other Assiut University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05809089.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing